Heidi Carias

Novartis (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index873citations20works12.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(8), Ubiquitin and proteasome pathways(5), Chronic Lymphocytic Leukemia Research(5), Chronic Myeloid Leukemia Treatments(5), PI3K/AKT/mTOR signaling in cancer(4)

Publications20 total

Identification of Potent, Broad-Spectrum Coronavirus Main Protease Inhibitors for Pandemic Preparedness
Journal of Medicinal Chemistry·2024· 12 citedOpen Access
Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation
JCI Insight·2023· 5 citedOpen Access
Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors
JAMA Oncology·2021· 38 citedOpen Access
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Cancer Discovery·2018· 135 citedOpen Access
Abstract 4711: Broad anti-tumor activity of a novel BET bromodomain inhibitor
Cancer Research·2016
KRAS insertion mutations are oncogenic and exhibit distinct functional properties
Nature Communications·2016· 17 citedOpen Access
RAF inhibitors that evade paradoxical MAPK pathway activation
Nature·2015· 374 cited
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
Cancer Discovery·2015· 197 citedOpen Access
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Proceedings of the National Academy of Sciences·2013· 95 citedOpen Access
Abstract 553: Discovery of novel TRK/FMS dual inhibitors as therapeutic candidates for pancreatic cancer
Cancer Research·2011

Frequent Co-authors

Gideon Bollag(19), Wayne Spevak(17), Gaston Habets(17), Prabha N. Ibrahim(17), Jiazhong Zhang(16), Garson Tsang(16), Rafe Shellooe(16), Bernice Matusow(15), Adhirai Marimuthu(11), Todd Ewing(10), Marika Nespi(10), Songyuan Shi(9), Laura Sanftner(9), Elizabeth A. Burton(8), Brian L. West(8), Ying Zhang(8), Paul Severson(8), B. J. Powell(8), Ben Powell(7), Hatice Gülçin Özer(7)